Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant Acinetobacter baumannii in mice

Frontiers in Microbiology

Volumn 8, Issue JAN, 2018, Pages

  Hua, Yunfen ^a,b   Luo, Tingting ^a,b   Yang, Yiqi ^b   Dong, Dong ^c   Wang, Rui ^b   Wang, Yanjun ^b   Xu, Mengsha ^a,b   Guo, Xiaokui ^b   Hu, Fupin ^c   He, Ping ^b  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Bacteriophage; Carbapenem resistant Acinetobacter baumannii (CRAB); Lung infection; Mouse model; Phagotherapy

Indexed keywords

CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; INTERLEUKIN 6; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TUMOR NECROSIS FACTOR;

ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIOLYSIS; BACTERIOPHAGE; BACTERIUM ISOLATION; BRONCHOALVEOLAR LAVAGE FLUID; ENDOTRACHEAL INTUBATION; ENZYME LINKED IMMUNOSPOT ASSAY; HISTOPATHOLOGY; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NONHUMAN; OPEN READING FRAME; PH; PHAGE THERAPY; TRANSMISSION ELECTRON MICROSCOPY; WHOLE GENOME SEQUENCING;

EID: 85040449884     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2017.02659     Document Type: Article

References (51)

1. Adams-Haduch, J. M., Onuoha, E. O., Bogdanovich, T., Tian, G. B., Marschall, J., Urban, C. M., et al. (2011). Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J. Clin. Microbiol. 49, 3849-3854. doi: 10.1128/JCM.00619-11
2. An, J. H., Kim, Y. H., Moon, J. E., Jeong, J. H., Kim, S. H., Kang, S. J., et al. (2017). Active surveillance for carbapenem-resistant Acinetobacter baumannii in a medical intensive care unit: Can it predict and reduce subsequent infections and the use of colistin? Am. J. Infect. Control. 45, 667-672. doi: 10.1016/j.ajic.2017.01.016
3. Atici, S., Soysal, A., Kepenekli Kadayifci, E., Karaaslan, A., Akkoc, G., Yakut, N., et al. (2016). Healthcare-associated infections in a newly opened pediatric intensive care unit in Turkey: results of four-year surveillance. J. Infect. Dev. Ctries. 10, 254-259. doi: 10.3855/jidc.7517
4. Besemer, J., Lomsadze, A., and Borodovsky, M. (2001). GeneMarkS: a self-training method for prediction of gene starts in microbial genomes. Implications for finding sequence motifs in regulatory regions. Nucleic Acids Res. 29, 2607-2618
5. Buser, G. L., Cassidy, P. M., Cunningham, M. C., Rudin, S., Hujer, A. M., Vega, R., et al. (2017). Failure to communicate: transmission of extensively drug-resistant bla OXA-237-containing Acinetobacter baumannii-multiple facilities in Oregon, 2012-2014. Infect. Control Hosp. Epidemiol. 38, 1335-1341. doi: 10.1017/ice.2017.189
6. Cao, F., Wang, X., Wang, L., Li, Z., Che, J., Wang, L., et al. (2015). Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res. Int. 2015:752930. doi: 10.1155/2015/752930
7. Chanishvili, N. (2016). Bacteriophages as therapeutic and prophylactic means: summary of the soviet and post soviet experiences. Curr. Drug Deliv. 13, 309-323. doi: 10.2174/156720181303160520193946
8. Chiang, S. R., Chuang, Y. C., Tang, H. J., Chen, C. C., Chen, C. H., Lee, N. Y., et al. (2009). Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit. Care Med. 37, 2590-2595. doi: 10.1097/CCM.0b013e3181a0f8e1
9. CLSI (2017). 'Performance standards for antimicrobial susceptibility testing, ' in Proceedings of the 27th Informational Supplement M100-S20 (Wayne, PA: Clinical and Laboratory Standards Institute)
10. Cooper, C. J., Khan Mirzaei, M., and Nilsson, A. S. (2016). Adapting drug approval pathways for bacteriophage-based therapeutics. Front. Microbiol. 7:1209. doi: 10.3389/fmicb.2016.01209
11. Cui, Z., Feng, T., Gu, F., Li, Q., Dong, K., Zhang, Y., et al. (2017). Characterization and complete genome of the virulent Myoviridae phage JD007 active against a variety of Staphylococcus aureus isolates from different hospitals in Shanghai, China. Virol. J. 14:26. doi: 10.1186/s12985-017-0701-0
12. Dalla-Costa, L. M., Coelho, J. M., Souza, H. A., Castro, M. E., Stier, C. J. N., Bragagnolo, K. L., et al. (2003). Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J. Clin. Microbiol. 41, 3403-3406. doi: 10.1128/jcm.41.7.3403-3406.2003
13. Dublanchet, A., and Fruciano, E. (2008). A short history of phage therapy. Med. Mal. Infect. 38, 415-420. doi: 10.1016/j.medmal.2008.06.016
14. Eveillard, M., Soltner, C., Kempf, M., Saint-Andre, J. P., Lemarie, C., Randrianarivelo, C., et al. (2010). The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. J. Infect. 60, 154-161. doi: 10.1016/j.jinf.2009.09.004
15. Gachomo, E. W., Jimenez-Lopez, J. C., Baptiste, L. J., and Kotchoni, S. O. (2014). GIGANTUS1 (GTS1), a member of transducin/WD40 protein superfamily, controls seed germination, growth and biomass accumulation through ribosome-biogenesis protein interactions in Arabidopsis thaliana. BMC Plant Biol. 14:37. doi: 10.1186/1471-2229-14-37
16. Garcia-Heredia, I., Rodriguez-Valera, F., and Martin-Cuadrado, A. B. (2013). Novel group of podovirus infecting the marine bacterium Alteromonas macleodii. Bacteriophage 3:e24766. doi: 10.4161/bact.24766
17. Garnacho-Montero, J., and Amaya-Villar, R. (2010). Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr. Opin. Infect. Dis. 23, 332-339. doi: 10.1097/QCO.0b013e32833ae38b
18. Gaynes, R., Edwards, J. R., and National Nosocomial Infections Surveillance System (2005). Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41, 848-854. doi: 10.1086/432803
19. Gu, J., Li, X., Yang, M., Du, C., Cui, Z., Gong, P., et al. (2016). Therapeutic effect of Pseudomonas aeruginosa phage YH30 on mink hemorrhagic pneumonia. Vet. Microbiol. 190, 5-11. doi: 10.1016/j.vetmic.2016.03.016
20. Hatfull, G. F. (2008). Bacteriophage genomics. Curr. Opin. Microbiol. 11, 447-453. doi: 10.1016/j.mib.2008.09.004
21. Hu, F. P., Guo, Y., Zhu, D. M., Wang, F., Jiang, X. F., Xu, Y. C., et al. (2016). Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin. Microbiol. Infect. 22(Suppl. 1), S9-S14. doi: 10.1016/j.cmi.2016.01.001
22. Jacobs, A. C., Thompson, M. G., Black, C. C., Kessler, J. L., Clark, L. P., McQueary, C. N., et al. (2014). AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. mBio 5:e1076-14. doi: 10.1128/mBio.01076-14
23. Jeon, J., Ryu, C. M., Lee, J. Y., Park, J. H., Yong, D., and Lee, K. (2016). In vivo application of bacteriophage as a potential therapeutic agent to control OXA-66-Like carbapenemase-producing Acinetobacter baumannii strains belonging to sequence type 357. Appl. Environ. Microbiol. 82, 4200-4208. doi: 10.1128/AEM.00526-16
24. Kitti, T., Thummeepak, R., Thanwisai, A., Boonyodying, K., Kunthalert, D., Ritvirool, P., et al. (2014). Characterization and detection of endolysin gene from three Acinetobacter baumannii bacteriophages isolated from sewage water. Indian J Microbiol. 54, 383-388. doi: 10.1007/s12088-014-0472-x
25. Kollef, K. E., Schramm, G. E., Wills, A. R., Reichley, R. M., Micek, S. T., and Kollef, M. H. (2008). Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134, 281-287. doi: 10.1378/chest.08-1116
26. Kvachadze, L., Balarjishvili, N., Meskhi, T., Tevdoradze, E., Skhirtladze, N., Pataridze, T., et al. (2011). Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb. Biotechnol. 4, 643-650. doi: 10.1111/j.1751-7915.2011.00259.x
27. Kwiatek, M., Parasion, S., Rutyna, P., Mizak, L., Gryko, R., Niemcewicz, M., et al. (2017). Isolation of bacteriophages and their application to control Pseudomonas aeruginosa in planktonic and biofilm models. Res. Microbiol. 168, 194-207. doi: 10.1016/j.resmic.2016.10.009
28. Lu, T. K., and Koeris, M. S. (2011). The next generation of bacteriophage therapy. Curr. Opin. Microbiol. 14, 524-531. doi: 10.1016/j.mib.2011.07.028
29. Luo, R., Liu, B., Xie, Y., Li, Z., Huang, W., Yuan, J., et al. (2012). SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. Gigascience 1:18. doi: 10.1186/2047-217X-1-18
30. Ma, Y., Li, E., Qi, Z., Li, H., Wei, X., Lin, W., et al. (2016). Isolation and molecular characterisation of Achromobacter phage phiAxp-3, an N4-like bacteriophage. Sci. Rep. 6:24776. doi: 10.1038/srep24776
31. Manepalli, S., Gandhi, J. A., Ekhar, V. V., Asplund, M. B., Coelho, C., and Martinez, L. R. (2013). Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis. J. Med. Microbiol. 62, 1747-1754. doi: 10.1099/jmm.0.060004-0
32. Maragakis, L. L., and Perl, T. M. (2008). Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46, 1254-1263. doi: 10.1086/529198
33. Mendes, J. J., Leandro, C., Mottola, C., Barbosa, R., Silva, F. A., Oliveira, M., et al. (2014). In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections. J. Med. Microbiol. 63, 1055-1065. doi: 10.1099/jmm.0.071753-0
34. Merabishvili, M., Pirnay, J. P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., et al. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLOS ONE 4:e4944. doi: 10.1371/journal.pone.0004944
35. Naaby-Hansen, S., Mandal, A., Wolkowicz, M. J., Sen, B., Westbrook, V. A., Shetty, J., et al. (2002). CABYR, a novel calcium-binding tyrosine phosphorylation-regulated fibrous sheath protein involved in capacitation. Dev. Biol. 242, 236-254. doi: 10.1006/dbio.2001.0527
36. Oduor, J. M., Onkoba, N., Maloba, F., Arodi, W. O., and Nyachieo, A. (2016). Efficacy of lytic Staphylococcus aureus bacteriophage against multidrug-resistant Staphylococcus aureus in mice. J. Infect. Dev. Ctries. 10, 1208-1213. doi: 10.3855/jidc.7931
37. Oliveira, H., Sillankorva, S., Merabishvili, M., Kluskens, L. D., and Azeredo, J. (2015). Unexploited opportunities for phage therapy. Front. Pharmacol. 6:180. doi: 10.3389/fphar.2015.00180
38. Pantopoulou, A., Giamarellos-Bourboulis, E. J., Raftogannis, M., Tsaganos, T., Dontas, I., Koutoukas, P., et al. (2007). Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int. J. Antimicrob. Agents 29, 51-55. doi: 10.1016/j.ijantimicag.2006.09.009
39. Queenan, A. M., and Bush, K. (2007). Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 20, 440-458. doi: 10.1128/CMR.00001-07 table of contents
40. Regeimbal, J. M., Jacobs, A. C., Corey, B. W., Henry, M. S., Thompson, M. G., Pavlicek, R. L., et al. (2016). Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob. Agents Chemother. 60, 5806-5816. doi: 10.1128/AAC.02877-15
41. Sarhan, W. A., and Azzazy, H. M. (2015). Phage approved in food, why not as a therapeutic? Expert Rev. Anti. Infect. Ther. 13, 91-101. doi: 10.1586/14787210.2015.990383
42. Sarker, S. A., Berger, B., Deng, Y., Kieser, S., Foata, F., Moine, D., et al. (2017). Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh. Environ. Microbiol. 19, 237-250. doi: 10.1111/1462-2920.13574
43. Sasikala, D., and Srinivasan, P. (2016). Characterization of potential lytic bacteriophage against Vibrio alginolyticus and its therapeutic implications on biofilm dispersal. Microb. Pathog. 101, 24-35. doi: 10.1016/j.micpath.2016.10.017
44. Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., et al. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61:e954-17. doi: 10.1128/AAC.00954-17
45. Skurnik, M., and Strauch, E. (2006). Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296, 5-14. doi: 10.1016/j.ijmm.2005.09.002
46. Sullivan, M. J., Petty, N. K., and Beatson, S. A. (2011). Easyfig: a genome comparison visualizer. Bioinformatics 27, 1009-1010. doi: 10.1093/bioinformatics/btr039
47. Takemura-Uchiyama, I., Uchiyama, J., Osanai, M., Morimoto, N., Asagiri, T., Ujihara, T., et al. (2014). Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice. Microbes Infect. 16, 512-517. doi: 10.1016/j.micinf.2014.02.011
48. Vieira, A., Silva, Y. J., Cunha, A., Gomes, N. C., Ackermann, H. W., and Almeida, A. (2012). Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments. Eur. J. Clin. Microbiol. Infect. Dis. 31, 3241-3249. doi: 10.1007/s10096-012-1691-x
49. Wang, J. B., Lin, N. T., Tseng, Y. H., and Weng, S. F. (2016). Genomic characterization of the novel Aeromonas hydrophila phage Ahp1 suggests the derivation of a new subgroup from phiKMV-Like family. PLOS ONE 11:e0162060. doi: 10.1371/journal.pone.0162060
50. Wang, Y., Mi, Z., Niu, W., An, X., Yuan, X., Liu, H., et al. (2016). Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia. Future Microbiol. 11, 631-641. doi: 10.2217/fmb.16.11
51. Yan, J., Mao, J., and Xie, J. (2014). Bacteriophage polysaccharide depolymerases and biomedical applications. BioDrugs 28, 265-274. doi: 10.1007/s40259-013-0081-y